Is Yervoy's Patient Assistance Discount Time-Limited?
Yervoy (ipilimumab), Bristol Myers Squibb's immunotherapy for melanoma and other cancers, offers discounts through programs like the Bristol Myers Squibb Patient Assistance Foundation and copay cards. These are not permanently time-limited for eligible patients but have specific expiration rules tied to enrollment periods, treatment cycles, or program updates.
Eligibility for free or discounted Yervoy via the BMS Access Support program lasts up to 12 months per approval, renewable annually with proof of financial need and ongoing treatment. Copay savings cards provide up to $25,000 in assistance per calendar year, resetting January 1, but expire after 48 months from activation or if unused for 180 days.[1]
How Long Do Yervoy Copay Cards Last?
Standard Yervoy copay cards activate for immediate use and remain valid for 48 months. They pause if no claims are filed for 180 consecutive days, requiring reactivation. Commercial insurance patients pay as little as $0 out-of-pocket until the annual cap hits, then revert to standard costs. Medicare patients qualify for alternative low-income subsidies without time caps but must reapply yearly.[1][2]
What Happens When Yervoy Discounts Expire?
Expired cards or denied renewals mean full copay resumption, often $10,000+ per infusion depending on dose (3 mg/kg every 3 weeks). Patients can reapply immediately via BMS Access Support (1-800-861-0048) or explore state programs. Uninsured patients get free Yervoy indefinitely if income-qualified (<500% federal poverty level), with no fixed end date.[2]
Why Do Yervoy Discounts Have Renewal Requirements?
Programs tie assistance to current medical need and finances to comply with anti-kickback laws. Changes in insurance, income, or FDA approvals trigger reviews. During shortages (like 2022-2023), priority went to active patients, indirectly limiting new enrollments.[3]
Yervoy Patent Timeline and Generic/Biosimilar Impact on Pricing
Yervoy's core composition patent (US 7,759,061) expires in 2028 in the US, with potential extensions to 2030 via pediatric exclusivity. Manufacturing patents last until 2035. No generics yet; first biosimilars unlikely before 2029 amid ongoing litigation from BMS against challengers like Samsung Bioepis. Expiry could cut prices 30-50%, reducing reliance on discounts.[4]
Alternatives if Yervoy Discounts Run Out
| Option | Coverage | Time Limit | Cost Savings |
|--------|----------|------------|--------------|
| Opdivo + Yervoy combo copay (BMS) | Commercial only | Annual $25K cap, 48-mo card | Up to $0 copay |
| Neulasta Onpro (similar immuno) | All payers | Varies by sponsor | 80% off list |
| Keytruda patient support (Merck) | PD-1 rival | No annual cap for commercial | $0 after $0 deductible |
| State ADAP programs | Uninsured/low-income | Ongoing with re-enrollment | Free for qualifying cancers |
Switching to rivals like Keytruda (pembrolizumab) avoids Yervoy-specific limits but requires doctor approval due to different mechanisms (CTLA-4 vs PD-1 inhibition).[2][4]
[1]: BMS Access Support - Yervoy Copay Program
[2]: Yervoy Patient Assistance Foundation
[3]: FDA Drug Shortages Database - Ipilimumab
[4]: DrugPatentWatch.com - Yervoy Patents